155 related articles for article (PubMed ID: 18678495)
1. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
Pick A; Müller H; Wiese M
Bioorg Med Chem; 2008 Sep; 16(17):8224-36. PubMed ID: 18678495
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.
Marighetti F; Steggemann K; Hanl M; Wiese M
ChemMedChem; 2013 Jan; 8(1):125-35. PubMed ID: 23150210
[TBL] [Abstract][Full Text] [Related]
3. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
4. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
[TBL] [Abstract][Full Text] [Related]
5. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
[TBL] [Abstract][Full Text] [Related]
6. Specific inhibitors of the breast cancer resistance protein (BCRP).
Pick A; Klinkhammer W; Wiese M
ChemMedChem; 2010 Sep; 5(9):1498-505. PubMed ID: 20632361
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
Pick A; Müller H; Mayer R; Haenisch B; Pajeva IK; Weigt M; Bönisch H; Müller CE; Wiese M
Bioorg Med Chem; 2011 Mar; 19(6):2090-102. PubMed ID: 21354800
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation.
Singh MS; Juvale K; Wiese M; Lamprecht A
Eur J Pharm Sci; 2015 Sep; 77():1-8. PubMed ID: 25976226
[TBL] [Abstract][Full Text] [Related]
9. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
Juvale K; Pape VF; Wiese M
Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540
[TBL] [Abstract][Full Text] [Related]
10. Grid-independent Descriptors (GRIND) Analysis and SAR Guided Molecular Docking Studies to Probe Selectivity Profiles of Inhibitors of Multidrug Resistance Transporters ABCB1 and ABCG2.
Shafi T; Jabeen I
Curr Cancer Drug Targets; 2017; 17(2):177-190. PubMed ID: 27585695
[TBL] [Abstract][Full Text] [Related]
11. Scaffold identification of a new class of potent and selective BCRP inhibitors.
Marighetti F; Steggemann K; Karbaum M; Wiese M
ChemMedChem; 2015 Apr; 10(4):742-51. PubMed ID: 25735648
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach.
Nicolle E; Boccard J; Guilet D; Dijoux-Franca MG; Zelefac F; Macalou S; Grosselin J; Schmidt J; Carrupt PA; Di Pietro A; Boumendjel A
Eur J Pharm Sci; 2009 Aug; 38(1):39-46. PubMed ID: 19501160
[TBL] [Abstract][Full Text] [Related]
13. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).
Kannan P; Telu S; Shukla S; Ambudkar SV; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
ACS Chem Neurosci; 2011 Feb; 2(2):82-9. PubMed ID: 22778859
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
Juvale K; Stefan K; Wiese M
Eur J Med Chem; 2013 Sep; 67():115-26. PubMed ID: 23851114
[TBL] [Abstract][Full Text] [Related]
15. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
16. Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2).
Puentes CO; Höcherl P; Kühnle M; Bauer S; Bürger K; Bernhardt G; Buschauer A; König B
Bioorg Med Chem Lett; 2011 Jun; 21(12):3654-7. PubMed ID: 21570282
[TBL] [Abstract][Full Text] [Related]
17. Quinoline carboxamide-type ABCG2 modulators: indole and quinoline moieties as anilide replacements.
Bauer S; Ochoa-Puentes C; Sun Q; Bause M; Bernhardt G; König B; Buschauer A
ChemMedChem; 2013 Nov; 8(11):1773-8. PubMed ID: 24039190
[TBL] [Abstract][Full Text] [Related]
18. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
Erić S; Kalinić M; Ilić K; Zloh M
SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255
[TBL] [Abstract][Full Text] [Related]
19. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y
Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398
[TBL] [Abstract][Full Text] [Related]
20. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]